These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

785 related items for PubMed ID: 24081439

  • 1. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.
    Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M, Flabouris K, Wechalekar MD, Lee AT, Cleland LG.
    Ann Rheum Dis; 2015 Jan; 74(1):89-95. PubMed ID: 24081439
    [Abstract] [Full Text] [Related]

  • 2. Plasma n-3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritis.
    Proudman SM, Cleland LG, Metcalf RG, Sullivan TR, Spargo LD, James MJ.
    Br J Nutr; 2015 Sep 28; 114(6):885-90. PubMed ID: 26283657
    [Abstract] [Full Text] [Related]

  • 3. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct 28; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 4. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Østergaard M, Stengaard-Pedersen K, OPERA Study-Group.
    Ann Rheum Dis; 2014 Apr 28; 73(4):654-61. PubMed ID: 23434570
    [Abstract] [Full Text] [Related]

  • 5. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, Porter DR.
    Arthritis Rheum; 2008 May 28; 58(5):1310-7. PubMed ID: 18438851
    [Abstract] [Full Text] [Related]

  • 6. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R.
    Ann Rheum Dis; 2015 Jan 28; 74(1):27-34. PubMed ID: 25359382
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
    O'Dell JR, Haire C, Erikson N, Drymalski W, Palmer W, Maloley P, Klassen LW, Wees S, Moore GF.
    J Rheumatol Suppl; 1996 Mar 28; 44():72-4. PubMed ID: 8833058
    [Abstract] [Full Text] [Related]

  • 8. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T, FIN-RACo Trial Group.
    Arthritis Rheum; 2009 May 28; 60(5):1222-31. PubMed ID: 19404945
    [Abstract] [Full Text] [Related]

  • 9. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T, Asikainen J, Hannonen P, Yli-Kerttula T, Ekman P, Pirilä L, Kuusalo L, Mali M, Puurtinen-Vilkki M, Kortelainen S, Paltta J, Taimen K, Kauppi M, Laiho K, Nyrhinen S, Mäkinen H, Isomäki P, Uotila T, Aaltonen K, Kautiainen H, Sokka T.
    Scand J Rheumatol; 2017 Nov 28; 46(6):425-431. PubMed ID: 28367663
    [Abstract] [Full Text] [Related]

  • 10. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
    Schoels M, Kapral T, Stamm T, Smolen JS, Aletaha D.
    Ann Rheum Dis; 2007 Aug 28; 66(8):1059-65. PubMed ID: 17307765
    [Abstract] [Full Text] [Related]

  • 11. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
    Karlsson JA, Neovius M, Nilsson JÅ, Petersson IF, Bratt J, van Vollenhoven RF, Ernestam S, Geborek P.
    Ann Rheum Dis; 2013 Dec 28; 72(12):1927-33. PubMed ID: 23196701
    [Abstract] [Full Text] [Related]

  • 12. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L, Katikireddi VS, Shankaranarayana S, Su KY, Duggan E, Videm V, Pahau H, Thomas R.
    Intern Med J; 2015 Dec 28; 45(12):1266-73. PubMed ID: 26384029
    [Abstract] [Full Text] [Related]

  • 13. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
    O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G.
    Arthritis Rheum; 2002 May 28; 46(5):1164-70. PubMed ID: 12115219
    [Abstract] [Full Text] [Related]

  • 14. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J.
    Ann Intern Med; 2013 Aug 20; 159(4):253-61. PubMed ID: 24026258
    [Abstract] [Full Text] [Related]

  • 15. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
    Heimans L, Wevers-de Boer KV, Visser K, Goekoop RJ, van Oosterhout M, Harbers JB, Bijkerk C, Speyer I, de Buck MP, de Sonnaville PB, Grillet BA, Huizinga TW, Allaart CF.
    Ann Rheum Dis; 2014 Jul 20; 73(7):1356-61. PubMed ID: 23716067
    [Abstract] [Full Text] [Related]

  • 16. Therapies for active rheumatoid arthritis after methotrexate failure.
    O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, Anis AH, Leatherman S, Keystone E, CSP 551 RACAT Investigators.
    N Engl J Med; 2013 Jul 25; 369(4):307-18. PubMed ID: 23755969
    [Abstract] [Full Text] [Related]

  • 17. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
    Mary J, De Bandt M, Lukas C, Morel J, Combe B.
    J Rheumatol; 2017 Jun 25; 44(6):773-779. PubMed ID: 28412710
    [Abstract] [Full Text] [Related]

  • 18. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
    Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppänen O, Luosujärvi R, Luukkainen R, Karjalainen A, Blåfield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Möttönen T, NEO-RACo Study Group.
    Ann Rheum Dis; 2013 Jun 25; 72(6):851-7. PubMed ID: 22753402
    [Abstract] [Full Text] [Related]

  • 19. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
    O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley P, Klassen LW, Wees S, Klein H, Moore GF.
    N Engl J Med; 1996 May 16; 334(20):1287-91. PubMed ID: 8609945
    [Abstract] [Full Text] [Related]

  • 20. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, Proudman SM.
    J Rheumatol; 2008 Apr 16; 35(4):562-71. PubMed ID: 18322994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.